Madelaine Feldman, MD
Rheumatology · Metairie, LANPI 1588665400
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.7%. Reporting peaked in 2019 at $13,683 and has fallen 81.7% since, to $2,509 in 2025.
Across 351 payments — averaging $139.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- Lilly USA, LLC$9K
- E.r. Squibb & Sons, L.L.C.$7K
- Samsung Bioepis Co., Ltd.$5K
- UCB, Inc.$3K
- Biogen$3K
- plus $12K from 18 others
What the payments were for
- Consulting fees$24,38050%
- Speaking & faculty fees$10,07921%
- Travel & lodging$6,07612%
- Food & beverage$8,32017%
- Education$2831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 47 | $10,174 |
| Lilly USA, LLC | 21 | $9,360 |
| E.r. Squibb & Sons, L.L.C. | 21 | $7,221 |
| Samsung Bioepis Co., Ltd. | 2 | $4,550 |
| UCB, Inc. | 22 | $3,220 |
| Biogen | 1 | $2,570 |
| Johnson & Johnson(2 entities) | 32 | $2,268 |
| AbbVie | 70 | $2,225 |
| Aurinia Pharma U.S., Inc. | 5 | $1,562 |
| Merck | 1 | $1,300 |
| Gilead | 1 | $1,300 |
| Amgen(2 entities) | 45 | $1,190 |
| Novartis | 35 | $698 |
| AstraZeneca | 10 | $529 |
| Sanofi | 6 | $274 |
| GSK | 15 | $259 |
| Regeneron Healthcare Solutions, Inc. | 3 | $140 |
| Genentech USA, Inc. | 4 | $85 |
| Antares Pharma, Inc. | 4 | $69 |
| Boehringer Ingelheim | 1 | $49 |
| Bristol Myers Squibb | 2 | $41 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Oxford Immunotec USA Inc | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,137 in reported general payments places this provider in the 85th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 23 | $161,198 |
| Cevimeline Hcl | 25 | $4,764 |
| Hydroxychloroquine Sulfate | 119 | $4,377 |
| Pilocarpine Hcl | 59 | $4,327 |
| MethotrexateMethotrexate Sodium | 143 | $2,356 |
| Mycophenolate Mofetil | 19 | $2,088 |
| Leflunomide | 20 | $1,680 |
| Ibandronate Sodium | 16 | $622 |
| Prednisone | 82 | $559 |
| Gabapentin | 36 | $549 |
| Tramadol Hcl | 63 | $522 |
| Methylprednisolone | 38 | $351 |
| Celecoxib | 23 | $296 |
| Levothyroxine Sodium | 39 | $262 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 16 | $213 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Metairie
- Jerry PoundsMetairie$252K
- Louis PerdueMetairie$17K
- Austin FraserMetairie$12K
- Magdalena BudziakowskaMetairie$4K
- Aaron BroadwellShreveport$1.6M
- Ladislas LazaroLafayette$265K
- Carl GauthierHammond$219K
- Malik SpadyCovington$160K
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.